Technology in Cancer Research & Treatment最新文献

{"title":"Retraction Notice: Silencing of Long Non-Coding RNA FGD5-AS1 Inhibits the Progression of Non-Small Cell Lung Cancer by Regulating the miR-493-5p/DDX5 Axis.","authors":"","doi":"10.1177/15330338241311208","DOIUrl":"10.1177/15330338241311208","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241311208"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary Collaboration and Novel Technological Advances in Hadron Therapy.","authors":"Manjit Dosanjh, Alberto Degiovanni, Maria Monica Necchi, Elena Benedetto","doi":"10.1177/15330338241311859","DOIUrl":"10.1177/15330338241311859","url":null,"abstract":"<p><p>The battle against cancer remains a top priority for society, with an urgent need to develop therapies capable of targeting challenging tumours while preserving patient's quality of life. Hadron Therapy (HT), which employs accelerated beams of protons, carbon ions, and other charged particles, represents a significant frontier in cancer treatment. This modality offers superior precision and efficacy compared to conventional methods, delivering therapeutic the dose directly to tumours while sparing healthy tissue. Even though 350,000 patients have already been treated worldwide with protons and 50,000 with carbon ions, HT is still a relatively young field and more research as well as novel, cost-effective and compact accelerator technologies are needed to make this treatment more readily available globally. Interestingly the very first patient was irradiated with protons in September 1954, the same month and year CERN was founded. Both of these endeavours are embedded in cutting edge technologies and multidisciplinary collaboration. HT is finally gaining ground and, even after 70 years, the particle therapy field continues innovating and improving for the benefits of patients globally. Developing technologies that are both affordable and easy to use is key and would allow access to more patients. Advances in accelerator-driven Boron Neutron Capture Therapy (BNCT), image-guided hadron beams delivery, clinical trials and immunotherapy, together with the recent interest and advances in FLASH therapy, which is currently an experimental treatment modality that involves ultrahigh-dose rate delivery, are just a few examples of innovation that may eventually help to provide access to a larger number of patients.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241311859"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Genetics in the Arab World.","authors":"Waleed S Al Amri, Muna Al Jabri, Aisha Al Abri, Thomas A Hughes","doi":"10.1177/15330338251336829","DOIUrl":"https://doi.org/10.1177/15330338251336829","url":null,"abstract":"<p><p>Cancer remains a major global health burden, with incidence rates rising globally. The Arab world, which is often regarded as an underrepresented population in literature, shows distinct patterns in cancer incidences, genetics, and outcomes in comparison with Western populations. This review aims to highlight key genomic studies conducted in the Arab world. We describe the epidemiological and genetic landscape of cancer in the Arab populations, focusing on lung, breast, and colorectal cancers, given their prominence and distinctive patterns in the region. We utilised data from GLOBOCAN 2022 and published genomic studies to assess subregional incidence trends, identify significant mutations, and explore hereditary and early-onset cancers profiles. Breast, lung, and colorectal cancers dominate the cancer profile in the region, with disparities in genetic alterations when compared to global trends. Variation in <i>EGFR</i> mutation frequencies in lung cancer across diverse ethnicities in the MENA region is representative of the extreme heterogeneity in the Arab region. Variations in <i>BRCA1/2</i> mutation frequency, and unique founder mutations highlight breast cancer's particular regional genetic traits. Similarly, colorectal cancer studies show variations in mutational profiles, such as a low incidence of <i>BRAF</i> mutations and distinct epigenetic characteristics that represent region-specific disease pathways. Early-onset cancers, particularly breast and colorectal cancers, occur at higher rates than in Western populations and often diverge from the typical germline mutation patterns reported globally. The review emphasises the importance of conducting localised genetic studies in improving personalised medicine and public health strategies. Despite these efforts, significant gaps remain, particularly in understanding early-onset cancers and hereditary cancer genetic disorders, which are overrepresented in the region. Further research on the genetic basis of cancer in Arab populations is essential for advancing personalised treatment and improving cancer outcomes in these under-researched groups.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251336829"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Significance and Pathogenic Mechanisms of Long Non-Coding RNA TRPM2-AS in Cancers.","authors":"Shichen Huang, Bowen Li, Huanyu Chen, Cheng Rong, Zheng Yang, Xianqin Zhang","doi":"10.1177/15330338251315625","DOIUrl":"10.1177/15330338251315625","url":null,"abstract":"<p><p>Long non-coding RNAs (lncRNAs) are known to play vital roles in human cancers. LncRNA TRPM2-AS has been found to be upregulated in various types of cancers. The elevated levels of TRPM2-AS are associated with important clinicopathological parameters such as tumor size, tumor stage, and lymph node metastasis, revealing that TRPM2-AS could be a potential target for cancer diagnosis, prognosis and treatment. Moreover, TRPM2-AS is involved in regulating the cell proliferation, migration, invasion, apoptosis, drug or radio resistance by serving as a competing endogenous RNA, directly bounding to proteins and regulating multiple signaling pathways. In this review, we comprehensively summarize the latest knowledge on the aberrant expression of TRPM2-AS, the relationship between TRPM2-AS and clinical features, and the detailed mechanisms of potential functions of TRPM2-AS in various cancer types. The current study highlights the potential of TRPM2-AS as a prognostic and therapeutic target in cancers.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251315625"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deregulation of Exosomal miR-17, miR-20a and TGFBR2 in Head and Neck Cancer Patients.","authors":"Muhammad Rizwan, Ishrat Mahjabeen, Muhammad Shahbaz Haris, Fouzia Qayyum, Mahmood Akhtar Kayani","doi":"10.1177/15330338251323314","DOIUrl":"10.1177/15330338251323314","url":null,"abstract":"<p><p><b>Introduction:</b> Exosomes play significant roles in transferring cargo materials like proteins, RNAs (including miRNAs), and DNA. However, the role of serum exosome shuttled RNAs and miRNAs in head and neck cancer (HNC) remains unclear. This study assessed the diagnostic and prognostic significance of exosomal <i>miR-17</i>, <i>miR-20a</i>, and <i>TGFBR2</i> in HNC patients. <b>Methods:</b> Exosomes were isolated, from 400 confirmed HNC patients and 400 healthy controls, and characterized by NTA, TEM, Immunolabelling, and ELISA. Quantitative PCR was used to check the expressions of exosomal molecules. Oxidative stress was also measured through ELISA in cancer patients and healthy controls. <b>Results:</b> Data analysis revealed significant dysregulation in the expressional levels of miR-17 (p < .0001), miR-20a (p = .0003), and <i>TGFBR2</i> (p = .0005), which were found associated with aggressiveness and poor survival of HNC patients. Spearman correlation revealed a positive statistically significant association between miR-20a versus miR-17 (r = 0.534; p < .01), while a negative correlation was found between <i>TGFBR2</i> versus miR-17 (r = -0.240; p = .015). Significantly decreased levels of peroxidase (POD) (p < .0001) and an increased level of 8-Oxoguanine (p < .0001) were observed. <b>Conclusion:</b> The results showed that these exosomal miRNAs and target gene may serve as potential and noninvasive diagnostic and prognostic markers for head and neck cancer patients.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251323314"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Specificity in Predicting Axillary Lymph Node Metastasis in Breast Cancer through an Interpretable Machine Learning Model with CEM and Ultrasound Integration.","authors":"Weimin Xu, Bowen Zheng, Chanjuan Wen, Hui Zeng, Sina Wang, Zilong He, Xin Liao, Weiguo Chen, Yingjia Li, Genggeng Qin","doi":"10.1177/15330338251334735","DOIUrl":"https://doi.org/10.1177/15330338251334735","url":null,"abstract":"<p><p>IntroductionThe study aims to evaluate the performance of an interpretable machine learning model in predicting preoperative axillary lymph node metastasis using primary breast cancer and lymph node features derived from contrast-enhanced mammography (CEM) and ultrasound (US) breast imaging reporting and data systems (BI-RADS).MethodsThis retrospective study included patients diagnosed with primary breast cancer. Two experienced radiologists extracted the BI-RADS features from the largest cross-section of the lesions and axillary lymph nodes based on CEM and US images, creating three datasets. Each dataset will train six base models to predict axillary lymph nodes, with pathological results serving as the gold standard. The top three models were used to train the five ensemble models. Additionally, SHapley Additive exPlanations (SHAP) was used to interpret the optimal model. The receiver-operating characteristic curve (ROC) and AUC were used to evaluate model performance.ResultsThis study involved 292 female patients, of whom 99 had axillary lymph node metastasis and 193 did not. The combination of CEM and ultrasound BI-RADS demonstrated the best performance in predicting axillary lymph node metastasis. Among these, the LightGBM achieved the highest AUC (0.762) and specificity (86.67%, while the ensemble model using RF as the meta-model had an AUC (0.754) and specificity (83.33%. The most important variables identified by SHAP were the long diameters of the lymph nodes in the CEM recombined image, along with their complete morphology in the low-energy image.ConclusionThe machine learning model using CEM and US BI-RADS features accurately predicted axillary lymph node metastasis before surgery, thereby serving as a valuable tool for clinical decision-making in patients with breast cancer.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251334735"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Inspiratory Breath-Hold Technique for Patients with Left-Sided Breast Cancer: Dosimetric Analysis, Clinical Evaluation, and Prediction.","authors":"Jing Shen, Kun Zhang, Xiangyin Meng, Bo Yang, Jiabin Ma, Ke Hu, Fuquan Zhang, Xiaorong Hou","doi":"10.1177/15330338251329120","DOIUrl":"https://doi.org/10.1177/15330338251329120","url":null,"abstract":"<p><p>IntroductionBreast radiotherapy is associated with a higher risk of cardiac diseases. Although deep inspiration breath-hold (DIBH) reduces the heart dose, it is underutilized. The selection of proper candidates for DIBH remains an unresolved issue. This study compared dosimetric parameters between free breathing (FB) and DIBH, monitored myocardial enzymes, and aimed to identify factors that can predict cardiac injury thus developing a method to identify proper patients for DIBH.MethodsThis is a prospective cohort study, enrolling 58 patients with left-sided breast cancer following breast-conserving surgery. All patients underwent computed tomography scans in both FB and DIBH states. A comparative analysis of dosimetric features between DIBH and FB was conducted. Myocardial enzyme was monitored until six months post-radiation therapy. T-tests were used to assess differences between the DIBH and the FB. Pearson correlation and receiver operating characteristic (ROC) analysis was conducted to identify factors associated with the subclinical acute cardiac injury.ResultsThe mean heart dose (MHD) of the DIBH group significantly dropped as compared to the FB group (3.81 Gy vs 1.65 Gy p = 0.001). Cardiac V40, V30, V25, V10, and V5 volumes also significantly reduced. 9(15.51%) patients exhibited increased myocardial enzyme, with cTnI being the most sensitive indicator. The heart dose was a predictor for the cardiac enzyme's elevation. The ROC curve analysis revealed an area under the curve of 0.6. With an MHD threshold of 2 Gy, both sensitivity and specificity exceeded 0.7.ConclusionDIBH significantly diminishes radiation exposure to the heart and LAD compared with FB. Cardiac enzyme analysis facilitates the early detection of cardiac injury following radiation therapy. An MHD threshold of less than 2 Gy is associated with a reduced risk of subclinical cardiac injury, potentially obviating the need for DIBH, which optimizes clinical efficiency and economic viability.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251329120"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining Immunotherapy with Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Analysis of Efficacy and Safety.","authors":"Guogang Gao, Meiling Sun, Zhongfei Yang, Jingyi Li, Huaijun Ji, Ge Yu","doi":"10.1177/15330338251329248","DOIUrl":"10.1177/15330338251329248","url":null,"abstract":"<p><p>BackgroundExtensive-stage small cell lung cancer (ES-SCLC) is a highly aggressive malignancy with poor prognosis. This study aimed to assess the efficacy of combining immunotherapy (IT) with Anlotinib in ES-SCLC patients.MethodsThis study was a multicenter retrospective cohort analysis. Survival outcomes were evaluated using Kaplan-Meier curves and Cox proportional hazards regression models.ResultsA total of 147 patients were included in the analysis. The median overall survival (mOS) for the cohort was 15.5 months (95% CI: 13.9-17.1). Patients in the chemotherapy(CT) plus IT group had an mOS of 17.8 months, compared to 12.6 months in the CT-alone group (p = 0.055). When stratified into CT + IT + Anlotinib, CT + IT, and CT-alone groups, the mOS were 18.5, 16.3, and 12.6 months, respectively, with the CT + IT + Anlotinib group demonstrating significantly improved OS compared to CT-alone (p = 0.044). The ORR and DCR for the entire cohort were 71.4% and 85.7%, respectively. Subgroup analysis revealed ORRs of 74.1% (CT + IT + Anlotinib), 73.9% (CT + IT), and 70.1% (CT-alone), with corresponding DCRs of 92.6%, 91.3%, and 82.5%. Multivariate analysis revealed that radiotherapy (RT, p = 0.003) and IT (p = 0.021) were independent prognostic factors for OS, while liver metastasis (p = 0.023) and RT (p = 0.018) were associated with PFS. Patients receiving RT in combination with CT showed markedly improved OS (17.5 vs 12.5 months; p = 0.002) and PFS (7.3 vs 6.3 months; p = 0.004). The incidence of adverse events was comparable across all groups (p = 0.721).ConclusionThe combined application of Anlotinib with IT and the combination of CT with RT both significantly improved survival outcomes in patients with ES-SCLC while maintaining a favorable safety profile. These findings warrant further investigation in future studies.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251329248"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"R Spondin in Cancer: Inducer or Impeder?","authors":"Vishnu Pulavarthy, Rohit Gundamaraju","doi":"10.1177/15330338251327465","DOIUrl":"10.1177/15330338251327465","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251327465"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zinc Finger Proteins in Colorectal Cancer: Insights into Molecular Mechanisms and Therapeutic Implications.","authors":"Chongyuan Lan, Ming Qiu, Minglin Lin","doi":"10.1177/15330338251334447","DOIUrl":"https://doi.org/10.1177/15330338251334447","url":null,"abstract":"<p><p>Colorectal cancer ranks as one of the most common malignancies globally, with mortality rates second only to lung cancer. Despite improvements in diagnostic and therapeutic approaches, long-term survival rates for colorectal cancer patients remain unsatisfactory. The onset and progression of this disease involve intricate molecular mechanisms, influenced by a range of biological factors. Zinc finger proteins play a critical role in these processes, impacting tumor development and patient prognosis. This review summarizes current research on zinc finger proteins in colorectal cancer, highlighting key findings and advancements in understanding their role in tumor biology.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251334447"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12032436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}